8 April
2024
Avacta Group
plc
("Avacta"
or "the Group" or "the Company")
AVA6000 Abstract Release by
AACR and Full Presentation Update
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted oncology drugs and
powerful diagnostics, today announces that the abstract of the
poster to be presented at the American Association of Cancer
Research ("AACR") Annual Meeting in San Diego, California on
Tuesday 9 April has now been released by AACR.
The poster presentation will be
based on data from the Phase 1a trial of AVA6000, a peptide drug
conjugate consisting of doxorubicin conjugated
with a peptide moiety that is specifically cleaved by fibroblast
activation protein (FAP) in the tumor
microenvironment.
Christina Coughlin, MD, PhD, Head of
Research & Development and Simon Bennett, DPhil, Chief Business
Officer, will be attending the conference with
colleagues.
Presentation details
Title: A Phase 1 trial of
AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor
microenvironment (TME)-targeted doxorubicin peptide drug conjugate
in patients with FAP-positive solid tumors
Session Title: First-in-Human
Phase 1 Clinical Trials 2
Session Date and Time: Tuesday
9 April 2024 9:00 AM - 12:30 PM (PDT)
Location: San Diego Convention
Center, San Diego CA USA
Abstract Presentation Number: CT188
First Author: Udai Banerji, MD,
PhD, The Institute of Cancer Research, London, and
The Royal Marsden NHS Foundation Trust
The presentation will include
updated data from the Phase 1 trial beyond those included in the
abstract. A copy of the abstract will be available on Avacta's
website at: https://avacta.com/about/scientific-resources/.
Copies of the poster will be
available on Avacta's website following the conference at:
https://avacta.com/about/resources/posters/.
Christina Coughlin will provide a
video presentation overview examining the data presented in the
poster. This will be available on 10th April at
https://avacta.com/investors/documents-presentations/.
Alastair Smith, Avacta Chief
Executive Officer, will also be hosting a webinar on Wednesday,
April 10 2024 at 5.30pm BST to discuss the data. Registration for
the event is via the following link:
https://www.turnerpope.com/register/
-Ends-
For
further information from Avacta Group plc, please
contact:
Avacta Group plc
Alastair Smith, Chief Executive
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44
(0) 1904 21 7070
www.avacta.com
|
|
|
Stifel Nicolaus Europe
Limited (Nomad and Joint Broker)
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / Ben Good
|
Tel: +44
(0) 207 710 7600
www.stifel.com
|
Peel Hunt (Joint Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
Tel: +44
(0) 207 418 8900
www.peelhunt.com
|
ICR Consilium (Media and
IR)
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
About AVA6000
AVA6000, Avacta Therapeutics' lead
oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety
that is specifically cleaved by fibroblast activation protein (FAP)
in the tumor microenvironment (TME). FAP is selectively
overexpressed in many solid tumors. The peptide
moiety (pre|CISIONTM) prevents cellular entry of
doxorubicin unless cleaved by FAP, thus enabling targeted delivery
of doxorubicin directly to the TME.
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company
focused on improving healthcare outcomes through targeted cancer
treatments and diagnostics.
Avacta has two divisions: an
oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, which is executing on an M&A led growth
strategy to create a full-spectrum diagnostics business focused on
supporting healthcare professionals and broadening access to
testing. Avacta's two proprietary platforms, Affimer® and
pre|CISION™ underpin its cancer therapeutics whilst the diagnostics
division leverages the Affimer® platform to drive competitive
advantage in its markets.
The pre|CISION™ platform modifies
chemotherapy to be activated only in the tumour tissue, reducing
systemic exposure and toxicity. This is achieved by harnessing an
enzyme called FAP which is highly upregulated in most solid tumours
compared with healthy tissues, turning chemotherapy into a
"precision medicine". The lead pre|CISION™ programme, AVA6000 a
tumour activated form of doxorubicin, is in Phase 1 studies and has
shown dramatic improvement in safety compared with standard
doxorubicin, and early signs of clinical activity.
To register for news alerts by email
go to https://avacta.com/investors/investor-news-email-alerts/